ImpediMed Ltd. Reports Multiple Changes in Director’s Interests
ImpediMed Ltd, a health care equipment and supplies company based in Australia, has recently reported several changes in the interests of its directors. These changes have been disclosed in accordance with the Australian Securities Exchange (ASX) listing rules and the Corporations Act. The company, which specializes in non-invasive medical devices for diagnosing and monitoring human disorders, particularly cancer survivors, has seen multiple directors update their interest notices.
Director Interest Updates
Ms. Christine Emmanuel-Donnelly
- Date of Last Notice: 07 March 2025
- ImpediMed Ltd has provided ASX with updated information regarding Ms. Emmanuel-Donnelly’s interests in the company’s securities. This update is in compliance with listing rule 3.19A.2 and section 205G of the Corporations Act.
Ms. Fiona Bones
- Date of Last Notice: 31 January 2025
- The company has submitted a change of interest notice for Ms. Fiona Bones, detailing her current interests in ImpediMed Ltd’s securities.
Mr. Andrew Grant
- Date of Last Notice: 31 January 2025
- Similar to Ms. Bones, Mr. Grant’s updated interests have been reported to ASX, ensuring transparency and compliance with regulatory requirements.
Ms. Janelle Delaney
- Date of Last Notice: 31 January 2025
- Ms. Delaney’s change in director’s interest has also been communicated to ASX, following the same regulatory guidelines.
Company Overview
ImpediMed Ltd operates in the Health Care Equipment & Supplies sector, focusing on innovative medical devices. The company is listed on the ASX All Markets and has a market capitalization of AUD 68,870,000. Despite a challenging financial year, with a price-to-earnings ratio of -3.26, ImpediMed continues to focus on its core mission of improving health outcomes for cancer survivors through advanced technology.
Market Performance
As of April 27, 2025, ImpediMed’s close price was AUD 0.036, with a 52-week high of AUD 0.093 on May 15, 2024, and a low of AUD 0.032 on April 16, 2025. The company’s financial performance reflects the broader challenges faced by the health care equipment sector, yet it remains committed to its strategic goals.
Conclusion
The recent updates on director interests highlight ImpediMed Ltd’s adherence to regulatory standards and its ongoing efforts to maintain transparency with shareholders and the market. As the company navigates its financial landscape, these updates serve as a reminder of its commitment to governance and innovation in health care technology.